Navigation Links
Iressa as Good as Chemotherapy for Lung Cancer
Date:11/21/2008

Daily pill easier to take, has fewer side effects than chemotherapy, experts say

FRIDAY, Nov. 21 (HealthDay News) -- The cancer-fighting pill Iressa works as well as chemotherapy as a second-line treatment for lung cancer, researchers report.

Although neither therapy prolongs survival beyond eight months, Iressa (gefitinib) causes fewer serious side effects and may be a better choice for patients who did not do well on their first round of chemotherapy.

"A pill, with less side effects, taken once a day, has similar activity to traditional chemotherapy given by vein every three weeks," said lead researcher Dr. Edward Kim, an assistant professor at the M. D. Anderson Cancer Center in Houston.

This finding should reassure doctors that they are not compromising effective therapy by using a pill, Kim said.

Iressa is not available in the United States, but a similar drug, Tarceva, is.

Iressa was first developed by AstraZeneca, but it failed to meet expectations. The National Cancer Institute ended clinical trials of the drug in 2005 because it failed to prolong the lives of lung cancer patients.

The latest finding has meaning for these patients, however, Kim said. "You can be treated for lung cancer. There are different therapies available, and they have different side-effect profiles," he said. "Chemotherapy will never be eliminated, but we are getting more options for targeted therapy; and people can live as normal a life as they can bearing the weight of lung cancer."

The report was published in the Nov. 22 issue of The Lancet.

In a head-to-head comparison, Kim's team randomly assigned 1,466 lung cancer patients who had undergone previous chemotherapy to daily doses of Iressa or the chemotherapy drug docetaxel once every three weeks.

The researchers found that survival in both groups of patients was about the same. Median survival for those taking Iressa was 7.6 months compared with eight months for patients receiving docetaxel. For patients with an EFGR gene mutation, average survival was 8.4 months for those on Iressa and 7.5 months for those receiving docetaxel.

However, there were significant differences in the side effects experienced by the treatment groups. For patients taking Iressa, the most common side effects were rash or acne. Among patients receiving docetaxel, the most common side effects were a blood disorder called neutropenia, personality disorders, and hair loss.

Dr. Michael Cullen, from the University Hospital Birmingham in the United Kingdom and author of an accompanying journal comment, noted that Iressa works differently than chemotherapy by targeting a receptor that is present in some patient's cancer cells.

"There are now two options that one can select from for patients in order to offer treatment that helps a bit following failure of first-line chemotherapy," Cullen said. "Survival overall is very poor, and, in fact, it's almost certainly the case that only a small minority of patients respond to either of the two treatments."

In addition, which patients would benefit most from Iressa isn't known, Cullen said. "In the study, tests didn't indicate that we are able to select treatment based on different characteristics of the patient."

Because survival time is short, Cullen thinks that doctors may want to decide which treatment to use based on how well a patient tolerated chemotherapy before.

"If they didn't tolerate chemotherapy very well, maybe the oncologist would opt for the oral therapy, whereas if they responded well to chemotherapy, the best choice might be to go with the chemotherapy," Cullen said.

More information

For more on lung cancer, visit the U.S. National Cancer Institute.



SOURCES: Edward Kim, M.D., assistant professor, M. D. Anderson Cancer Center, Houston; Michael Cullen, M.D., University Hospital Birmingham, U.K.; Nov. 22, 2008, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy
2. Chemotherapy may be culprit for fatigue in breast cancer survivors
3. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. To evade chemotherapy, some cancer cells mimic stem cells
5. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
6. PET scans can accurately detect a breast tumors response to chemotherapy
7. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
8. Medicare modernization act did not change chemotherapy as feared
9. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
10. Cancer conflict with chemotherapy treatment
11. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Iressa as Good as Chemotherapy for Lung Cancer
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery ... Arizona pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic ... , Dr. Olson says the decision to support the pageant in an ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched its ... by matching users with high quality water pipes within an ideal price range. The ... Inhale was founded by two brothers, Nick and Mike Hunter, who use medical cannabis ...
(Date:6/23/2016)... ... June 23, 2016 , ... An article ... a possible link between head and neck cancer in individuals with unhealthy oral hygiene ... were evaluated based on whether they had gum disease, brushed their teeth on a ...
(Date:6/23/2016)... ... June 23, 2016 , ... Virginia Beach resident Sean ... He turned towards the water to find peace and set out to accomplish a ... charity and turned to the internet. He came across the story of another special ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016  The National Pharmaceutical Council (NPC) ... health policy research organization as its newest member.  ... senior vice president and chief scientific officer, Mallinckrodt ... the NPC Board of Directors. ... has joined us in support of our efforts ...
(Date:6/23/2016)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a ... of primary and metastatic liver cancers, announces that the ... www.againsttheodds.eu - has been awarded a silver medal ... The website was developed as an education ... who are coping with the devastating diagnosis of cancer ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: AMAG ), IDEXX Laboratories Inc. (NASDAQ: ... ADRO ). Learn more about these stocks by accessing their ...
Breaking Medicine Technology: